These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 39067538)

  • 1. Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming.
    Li H; Xia Y; Zha H; Zhang Y; Shi L; Wang J; Huang H; Yue R; Hu B; Zhu J; Song Z
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct; 1870(7):167433. PubMed ID: 39067538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis.
    Srivastava SP; Li J; Kitada M; Fujita H; Yamada Y; Goodwin JE; Kanasaki K; Koya D
    Cell Death Dis; 2018 Sep; 9(10):997. PubMed ID: 30250024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes mellitus.
    Belosludtsev KN; Starinets VS; Belosludtsev MN; Mikheeva IB; Dubinin MV; Belosludtseva NV
    Mitochondrion; 2021 Jul; 59():246-254. PubMed ID: 34144205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Octyl itaconate attenuates renal tubular injury in db/db mice by activating Nrf2 and promoting PGC-1α-mediated mitochondrial biogenesis.
    Shao M; Chen J; Zhang F; Su Q; Lin X; Wang W; Chen C; Ren H; Zheng S; Hui S; Qin S; Ni Y; Zhong J; Yang J
    Ren Fail; 2024 Dec; 46(2):2403653. PubMed ID: 39291665
    [No Abstract]   [Full Text] [Related]  

  • 6. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes.
    Tang L; Wu Y; Tian M; Sjöström CD; Johansson U; Peng XR; Smith DM; Huang Y
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E563-E576. PubMed ID: 28811292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of pericyte metabolic reprogramming restricts the AKI to CKD transition.
    Xu C; Hong Q; Zhuang K; Ren X; Cui S; Dong Z; Wang Q; Bai X; Chen X
    Metabolism; 2023 Aug; 145():155592. PubMed ID: 37230215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes.
    Locatelli M; Zoja C; Zanchi C; Corna D; Villa S; Bolognini S; Novelli R; Perico L; Remuzzi G; Benigni A; Cassis P
    Sci Rep; 2020 May; 10(1):8418. PubMed ID: 32439965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dapagliflozin Ameliorates Renal Tubular Ferroptosis in Diabetes via SLC40A1 Stabilization.
    Huang B; Wen W; Ye S
    Oxid Med Cell Longev; 2022; 2022():9735555. PubMed ID: 35993021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of forkhead box O1 in renal tubular epithelial cells on endotoxin-induced acute kidney injury.
    Zhang M; Dong W; Li Z; Xiao Z; Xie Z; Ye Z; Liu S; Li R; Chen Y; Zhang L; Wang M; Liang H; Baihetiyaer R; Apaer R; Dong Z; Liang X
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F262-F272. PubMed ID: 33356954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Beneficial Effect of the SGLT2 Inhibitor Dapagliflozin in Alleviating Acute Myocardial Infarction-Induced Cardiomyocyte Injury by Increasing the Sirtuin Family SIRT1/SIRT3 and Cascade Signaling.
    Lin YH; Tsai WC; Chiu CC; Chi NY; Liu YH; Huang TC; Wu WT; Lin TH; Lai WT; Sheu SH; Hsu PC
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats.
    Oraby MA; El-Yamany MF; Safar MM; Assaf N; Ghoneim HA
    Biomed Pharmacother; 2019 Jan; 109():910-920. PubMed ID: 30551545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient inhibition of sodium-glucose cotransporter 2 after ischemia/reperfusion injury ameliorates chronic kidney disease.
    Martínez-Rojas MÁ; Balcázar H; González-Soria I; González-Rivera JM; Rodríguez-Vergara ME; Velazquez-Villegas LA; León-Contreras JC; Pérez-Villalva R; Correa F; Rosetti F; Bobadilla NA
    JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38516890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.